Zonisamide clinical trials: European experience
نویسندگان
چکیده
منابع مشابه
Zonisamide clinical trials: European experience
European clinical trials of zonisamide as adjunctive therapy for refractory partial seizures included a 12-week double-blind, placebo-controlled study and a 15-month open-label extension study. In the double-blind study, patients (n = 144) were randomized to placebo or zonisamide (400 mg QD) after baseline evaluation. Patients completing the double-bind study (n = 115) continued on open-label z...
متن کاملEfficacy of zonisamide: our experience
The current overview of zonisamide use and effectiveness is based on both a long-term prospective postmarketing survey and current zonisamide use at the Saitama Medical College, Department of Neuropsychiatry. Survey data, which were collected from individual physicians and 23 survey groups throughout Japan, assessed the effectiveness of zonisamide in 1631 patients. Zonisamide was highly effecti...
متن کاملReview of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures
Zonisamide is an antiepilepsy drug (AED) with both sodium and calcium channel-blocking properties. This dual mechanism may predict efficacy in some refractory patients, and a broad spectrum of action against different seizure types. Zonisamide has been commercially available in Japan since 1989, and became available in the United States for treatment of adults over the age of 12 with partial-on...
متن کاملZonisamide overview of the United States experience
Although established antiepilepsy drugs (AEDs) are efficacious and new drugs have become available to treat patients with epilepsy, at least 30% of all patients remain refractory to available treatment.1 Continued efforts to identify and develop new compounds for the treatment of epilepsy motivate all concerned because of the plight of so many patients. In the following sections, data are provi...
متن کاملEuropean & Developing Countries Clinical Trials Partnership (EDCTP)
EDCTP was established by the European Union in 2003. The first EDCTP program ran until 2015 and focused on HIV, tuberculosis (TB) and malaria. It supported numerous clinical trials that aimed to have a significant impact on the diagnosis, treatment and prevention of these diseases. In light of significant unmet medical needs, the scope of EDCTP was extended in 2014, now covering neglected infec...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Seizure
سال: 2004
ISSN: 1059-1311
DOI: 10.1016/j.seizure.2004.04.010